CA2983022C - High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells - Google Patents

High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells Download PDF

Info

Publication number
CA2983022C
CA2983022C CA2983022A CA2983022A CA2983022C CA 2983022 C CA2983022 C CA 2983022C CA 2983022 A CA2983022 A CA 2983022A CA 2983022 A CA2983022 A CA 2983022A CA 2983022 C CA2983022 C CA 2983022C
Authority
CA
Canada
Prior art keywords
cells
buffer
profiling
domain peptide
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2983022A
Other languages
English (en)
French (fr)
Other versions
CA2983022A1 (en
Inventor
Anthony Letai
Patrick BHOLA
Jeremy RYAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2983022A1 publication Critical patent/CA2983022A1/en
Application granted granted Critical
Publication of CA2983022C publication Critical patent/CA2983022C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA2983022A 2015-04-27 2016-04-27 High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells Active CA2983022C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153475P 2015-04-27 2015-04-27
US62/153,475 2015-04-27
PCT/US2016/029495 WO2016176288A1 (en) 2015-04-27 2016-04-27 High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells

Publications (2)

Publication Number Publication Date
CA2983022A1 CA2983022A1 (en) 2016-11-03
CA2983022C true CA2983022C (en) 2023-03-07

Family

ID=57198812

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2983022A Active CA2983022C (en) 2015-04-27 2016-04-27 High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells

Country Status (6)

Country Link
US (4) US10761086B2 (https=)
EP (2) EP3288964B1 (https=)
JP (3) JP6814745B2 (https=)
AU (2) AU2016253957C1 (https=)
CA (1) CA2983022C (https=)
WO (2) WO2016176299A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171809A1 (en) 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
CA2645853A1 (en) 2006-03-31 2007-11-01 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
JP6352924B2 (ja) 2012-09-19 2018-07-04 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ダイナミックｂｈ３プロファイリング
AU2014323526B2 (en) 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
CA2979999A1 (en) 2015-03-18 2016-09-22 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
HK1251655A1 (zh) 2015-04-20 2019-02-01 Tolero Pharmaceuticals, Inc. 通过线粒体分析预测对阿伏西地的应答
EP3288964B1 (en) 2015-04-27 2024-02-21 Dana-Farber Cancer Institute, Inc. High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
KR102608921B1 (ko) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. 생체 이용률이 증가된 알보시딥 프로드러그
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
WO2018017922A2 (en) 2016-07-22 2018-01-25 Massachusetts Institute Of Technology Selective bfl-1 peptides
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
AU2017379847B2 (en) 2016-12-19 2022-05-26 Sumitomo Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2020060975A1 (en) * 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides selective for bcl-2 family proteins
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
EP3931563A4 (en) * 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
WO2025212653A1 (en) * 2024-04-01 2025-10-09 Dana-Farber Cancer Institute, Inc. Methods including bh3 profiling of car t cells

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE365808T1 (de) 1995-07-28 2007-07-15 Marie Curie Cancer Care Transportproteine und deren verwendungen
JP3295431B2 (ja) 1995-10-24 2002-06-24 サングスタット メディカル コーポレイション 抗アルファ−ガラクトシルスクリーニング技術
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1015578A4 (en) 1997-09-17 2004-12-01 Walker And Eliza Hall Inst Of THERAPEUTIC MOLECULES
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1210098A1 (en) 1999-04-07 2002-06-05 Thomas Jefferson University Enhancement of peptide cellular uptake
AU6906100A (en) 1999-08-16 2001-03-13 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis
WO2002020568A2 (en) 2000-09-06 2002-03-14 Abbott Laboratories Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
WO2002069995A2 (en) 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
WO2003040168A2 (en) * 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
WO2003055515A1 (en) 2001-12-21 2003-07-10 Arius Research, Inc. Individualized anti-cancer antibodies
US20040171809A1 (en) 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1608969A4 (en) 2003-03-19 2007-06-06 Alfa Wassermann Inc SEPARATION AND ACCUMULATION OF SUB-CELLULAR COMPONENTS, AND PROTEINS WHICH ARE DRAWN THEREFROM
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
JP2005130867A (ja) 2005-02-16 2005-05-26 Mitokor ミトコンドリア内カルシウムを使用するスクリーニングアッセイ
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
US20070027175A1 (en) 2005-07-27 2007-02-01 Shaughnessy John Jr Antineoplastic activities of ellipticine and its derivatives
CA2645853A1 (en) 2006-03-31 2007-11-01 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
US8518635B2 (en) 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation
KR100786759B1 (ko) 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
US9360473B2 (en) 2006-08-16 2016-06-07 Eutropics Pharmaceuticals, Inc. Assay system to identify therapeutic agents
WO2008152405A2 (en) 2007-06-15 2008-12-18 The Queen's University Of Belfast Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases
JP2011501731A (ja) 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP2009240173A (ja) 2008-03-28 2009-10-22 Univ Of Tokushima パーキン蛋白の新規糖化因子
MX2011013385A (es) 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
WO2010147961A1 (en) 2009-06-15 2010-12-23 Precision Therapeutics, Inc. Methods and markers for predicting responses to chemotherapy
US20130122492A1 (en) 2011-11-14 2013-05-16 Kellbenx Inc. Detection, isolation and analysis of rare cells in biological fluids
US20150301053A1 (en) * 2012-05-10 2015-10-22 Eutropics Pharmaceuticals, Inc. Surrogate functional diagnostics test for cancer
US20150322479A1 (en) * 2012-06-20 2015-11-12 Cytospan Technologies Corporation Apparatus and method for quantification of replicative lifespan and observation of senescene
JP6352924B2 (ja) 2012-09-19 2018-07-04 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ダイナミックｂｈ３プロファイリング
JP6327662B2 (ja) 2012-09-26 2018-05-23 学校法人藤田学園 細胞表面タンパクを抗原とする抗体を測定する方法
EP3022222A4 (en) 2013-07-18 2017-06-07 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
AU2014323526B2 (en) 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
EP3288964B1 (en) 2015-04-27 2024-02-21 Dana-Farber Cancer Institute, Inc. High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
US11092602B2 (en) 2015-07-06 2021-08-17 Whitehead Institute For Biomedical Research Methods and compositions relating to proteasome inhibitor resistance
EP3931563A4 (en) 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING

Also Published As

Publication number Publication date
HK1252058A1 (en) 2019-05-10
WO2016176299A1 (en) 2016-11-03
US20210041419A1 (en) 2021-02-11
EP3289094B1 (en) 2024-06-05
US20180120297A1 (en) 2018-05-03
JP2018520638A (ja) 2018-08-02
US20210255167A1 (en) 2021-08-19
WO2016176288A1 (en) 2016-11-03
EP3288964B1 (en) 2024-02-21
EP3288964A1 (en) 2018-03-07
JP2018514210A (ja) 2018-06-07
US20180128813A1 (en) 2018-05-10
JP6814745B2 (ja) 2021-01-20
AU2016255749B2 (en) 2021-10-14
EP3288964A4 (en) 2018-10-31
AU2016253957C1 (en) 2021-04-01
EP3289094A1 (en) 2018-03-07
US11867688B2 (en) 2024-01-09
CA2983022A1 (en) 2016-11-03
AU2016253957B2 (en) 2020-10-22
HK1252055A1 (en) 2019-05-10
US10761086B2 (en) 2020-09-01
AU2016255749A1 (en) 2017-10-19
EP3289094A4 (en) 2018-10-31
CA2983024A1 (en) 2016-11-03
JP6802185B2 (ja) 2020-12-16
JP2021036915A (ja) 2021-03-11
AU2016253957A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
US11867688B2 (en) High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
EP1392342A1 (en) Global analysis of protein activities using proteome chips
US12529692B2 (en) Live cell imaging dynamic BH3 profiling
HK1252058B (en) High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
Rees et al. Identification of the cis-molecular neighbours of the immune checkpoint protein B7-H4 in the breast cancer cell-line SK-BR-3 by proteomic proximity labelling
CA2983024C (en) Compositions and methods for assessing toxicity using dynamic bh3 profiling
HK1252055B (en) Compositions and methods for assessing toxicity using dynamic bh3 profiling
KR101444995B1 (ko) 세포질 단백질의 단백질-단백질 상호작용을 확인하는 방법
Loo et al. Repair of CFTR folding defects with correctors that function as pharmacological chaperones
EP2981616B1 (en) Solid phase transfection of proteins and nucleic acids
WO2007058987A1 (en) Methods of identifying compounds that inhibit notch cleavage
KR101432714B1 (ko) 벤조안트라센 오염 검출을 위한 마커 및 키트
KR101119995B1 (ko) 단백질 상호작용 억제제 선별방법
Alsagaby Proteomics analysis of chronic lymphocytic leukaemia cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210122